Activation of PPAR-γ Ameliorates Pulmonary Arterial Hypertension Via Inducing Heme Oxygenase-1 and P21(waf1): an in Vivo Study in Rats.

Aims: Our previous study has indicated that activation of PPAR-gamma inhibits the proliferation of rat pulmonary artery smooth muscle cells (PASMCs) in vitro through inducing the expression of heme oxygenase-1 (HO-1), which in turn up-regulates the p21(WAF1) expression. In the present study, we intended to determine whether similar mechanisms have been involved in activation of PPAR-gamma inhibition of development of rat PAH model.Material and methods: Rat pulmonary arterial hypertension (PAH) model was established by subcutaneous injection of monocrotaline (MCT). Rosiglitazone was administered to activate PPAR-gamma. Zinc protoporphyria IX (ZnPP-IX), was used to confirm the role of HO-1 in mediating PPAR-gamma function. Parameters including the right ventricle systolic pressure (RVSP), the right ventricular hypertrophy (RVH) and the percentage of medial wall thickness were used to evaluate the development of PAH. Immunoblotting was used to determine the expression of HO-1 and p21(WAF1).Key findings: Rosiglitazone significantly decreased the RVSP and inhibited the RVH in MCT-induced rat PAH model, and partially inhibited the pulmonary vascular remodeling. These effects were coupled with the sequential increase of HO-1 and p21(WAF1) expressions by rosiglitazone.Significance: Activation of PPAR-gamma benefits PAH by inhibiting proliferation of PASMCs and reducing pulmonary vascular remodeling. The present study suggests that enhancing PPAR-gamma activity might have potential value in clinical treatment of PAH. (C) 2014 Elsevier Inc. All rights reserved.